Speaker

Sun Yuanyuan graduated from Nanjing University with 16 years of experience in omics industry and traditional drug screening platform development, providing genomic/proteomic research products and technical services for domestic universities, government agencies, hospitals, and third-party research institutions. In 2015, assembled a team to pioneer AI applications in novel target discovery and lead compound identification, subsequently developing a proprietary AI drug discovery platform based on logical algorithms. Founded DuoFortuna BioMed (Suzhou) Co., Ltd. in December 2020, currently advancing five drug pipelines targeting disease areas with unmet clinical needs including multiple sclerosis (MS), inflammatory bowel disease (IBD), Parkinson’s disease (PD), etc.

JP; MBBS(HK); ChM(Liv); FRCS(Eng, Edin, Glas, and Ire); FRCPCH; FHKAM (Surgery);HKAS member Prof. Paul K.H. Tam is a renowned surgeon, scientist, educator and university leader. He is Chair Professor and Vice-President of the Macau University of Science and Technology, and Emeritus Professor and Honorary Clinical Professor of the University of Hong Kong Professor Tam has special interests in minimal invasive surgery, genetics and regenerative medicine of birth defects especially Hirschsprung’s disease and biliary atresia. He has published 505 articles in internationally refereed journals with 35,314 citations and h-index = 66. He has received numerous awards including the 2017 Denis Browne Gold Medal- the highest award of the BAPS, the 2020 Rehbein Medal by the European Paediatric Surgeons’ Association.

Dr. Tan Yu Yan, Chief Physician in the Department of Neurology at Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine. Managing Editor of Translational Neurodegeneration journal. Her primary research focus is on the innovative diagnosis and treatment as well as the pathogenesis of neurodegenerative diseases such as Parkinson’s disease and multiple system atrophy. From 2014 to 2016, she worked as a visiting scholar at the University of Arizona, studying the role of epigenetics in the pathogenesis of Parkinson’s disease and Alzheimer’s disease.

In recent years, she has paid particular attention to the diagnostic and differential diagnostic roles of gut microbiota and metabolic products, as well as invasive and non-invasive neuromodulation of Parkinson’s disease and multiple system atrophy.

Dr. Tang Chang Yong is an Associate Researcher in the Department of Neurology at The 3rd Affiliated Hospital of Sun Yat-sen University (SYSU). A recipient of SYSU’s “Hundred Talents Program,” he is also a doctoral supervisor who earned his Ph.D. from the University of Chinese Academy of Sciences and completed postdoctoral training at Brown University in the USA. His primary research focuses on the roles of neural stem cells, astrocytes, and their microenvironment in the pathogenesis of neurodegenerative diseases, such as aging and Alzheimer’s disease (AD), as well as neuroimmunological diseases, including neuromyelitis optica spectrum disorder (NMOSD) and multiple sclerosis (MS). Dr. Tang has led several prestigious research projects, such as grants from the National Natural Science Foundation and a youth project under the “Innovation 2030 Brain Project.” His significant academic contributions include publishing over 20 papers as first or corresponding author in high-impact journals such as Neuron, Science Advances* (twice), and Molecular Psychiatry* (twice).

Jiawei Tang is the Co-founder and COO of Global Biopharma Partnerships. She holds a Master’s degree in Digital Transformation in Healthcare Management and brings over 15 years of extensive experience in the healthcare and life sciences industry, with a proven track record in sales,
corporate strategy, and marketing.

Her professional background includes 12 years in management roles at Pfizer, a global pharmaceutical leader, and one year as Commercial Strategy Director at Resolian, a renowned contract research organization (CRO). She has successfully led and implemented numerous brand transformation, corporate strategy, integrated marketing communications, and business innovation projects across major markets, including the United States, the United Kingdom, Australia, and China.

In addition to her professional work, Jiawei serves in volunteer leadership roles at several nonprofit healthcare organizations, including as a Geographic Expansion Leadership Member at the Healthcare Business Association, as an Advisory Borad member of One Patient One cure and as Vice President of the Chinese Biopharmaceutical Association Greater Philadelphia.

Mark Tang is the Managing Director of Good Health Capital, a healthcare PEVC firm with offices in New York and Shanghai, and Chairperson of World Biotech Capital LLC, a cross-border venture capital, M&A, licensing, and IPO advisory firm. Mark is also a co-founder of 111 Longevity LLC and Phagionics Inc. Originally from mainland China and educated in the US, Mark is a veteran Chinese biotech investor with over two decades of experience in the field of biotechnology as an entrepreneur, educator, advisor, and investor. He served as the biotech director at Rutgers Business School and as a lecturer at Rockefeller University. Mark has worked at investment banks, including Morgan Stanley Dean Witter and UBS PaineWebber. He is the author of “The Essential Biotech Investment Handbook,” which is published in both English and Chinese. Mark has co-founded three tech startups that have achieved successful exits. He holds degrees from NYU Stern School of Business and the Harvard T.H. Chan School of Public Health.

Mr. Tang Ming is the Executive Director and Chief Executive Officer of YNBY International Limited, bringing over 25 years of extensive experience in international market development. He specializes in formulating global strategies, establishing and leading local teams, and navigating regional regulations and business ecosystems to successfully launch new ventures. With deep expertise spanning marketing and sales, research and development, supply chain management, and go-to-market (GTM) execution, Mr. Tang has worked across Europe, North America, and the Asia-Pacific regions, collaborating with top-tier clients across diverse industry verticals.

Dr. Tang Naping is the Director of Toxicology Business Unit at InnoStar, with over 16 years of experience in toxicology research. Dr. Tang serves as a Standing Committee Member of the Safety Pharmacology Society, Chinese Pharmacological Society (CSPS), and a Council Member of the Shanghai Society of Toxicology. He has been awarded the Natural Science Award, Second Class, from the Ministry of Education, and the Shanghai Science and Technology Award, Second Prize. As the first or corresponding author, he has published 18 SCI-indexed papers.

Doctor, Associate Researcher, Supervisor of Master’s Degree Students, Future Leader of Key Discipline in Shanghai’s Traditional Chinese Medicine, Member of the Sensory and Motor Special Committee of the Chinese Neuroscience Society, and Young Member of the Brain Disease Branch of the Chinese Materia Medica Society. Mainly engaged in the research on the mechanism of refractory epilepsy and individualized treatment. Selected for the Chinese Materia Medica Young Talent Support Program, Shanghai Oriental Talent Young Program, Shanghai Outstanding Young Medical Talent, Shanghai Silver Snake Award Nomination Award and Silver Snake Award – Hengjie Special Support Program. Published 37 SCI papers as the first author, co-first author or corresponding author in academic journals such as J Hepatol, BJP, JMC and Acta Pharmacol Sin. As the first principal investigator, won the second prize of Shanghai Traditional Chinese Medicine Science. Has undertaken 4 National Natural Science Foundation projects and 4 provincial and ministerial projects.

Nicholas Teo is the General Manager of GSK Hong Kong & Macau. With almost 20 years of pharmaceutical experience and a proven track record in multiple countries, he has been instrumental in driving the company’s growth and the access of innovative medicines to patients in various countries. Nicholas started out as a medical sales representative in Singapore and has progressed to various key leadership positions throughout his career. This includes Business Unit Director roles in Singapore & Taiwan, where he led the local business to growth in Respiratory, Oncology and established portfolios and also above country roles such as Global Marketing Director & Global Market Access Director, based in the London HQ where he was responsible for brand and pricing strategies for various assets. He is known for his strategic vision, strong leadership skills, and dedication to fostering a collaborative and innovative work environment. Nicholas is Board Member of The Hong Kong Association of the Pharmaceutical Industry.